tiprankstipranks
Advertisement
Advertisement
Immutep Halts Key Lung Cancer Phase III Trial but Maintains Strong Cash Position and Pipeline Progress
PremiumCompany AnnouncementsImmutep Halts Key Lung Cancer Phase III Trial but Maintains Strong Cash Position and Pipeline Progress
1M ago
Immutep Faces Nasdaq Bid-Price Warning but Retains Dual Listings
Premium
Company Announcements
Immutep Faces Nasdaq Bid-Price Warning but Retains Dual Listings
1M ago
Immutep receives noncompliance notification from Nasdaq
Premium
The Fly
Immutep receives noncompliance notification from Nasdaq
1M ago
Immutep granted Orphan Drug Designation for eftilagimod alfa
PremiumThe FlyImmutep granted Orphan Drug Designation for eftilagimod alfa
2M ago
Immutep Advances First-in-Class LAG-3 Agonist IMP761 With Positive Phase I Progress
Premium
Company Announcements
Immutep Advances First-in-Class LAG-3 Agonist IMP761 With Positive Phase I Progress
2M ago
Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease
Premium
The Fly
Immutep sees progress from Phase I study of LAG-3 agonist for autoimmune disease
2M ago
Adobe downgraded, Nio upgraded: Wall Street’s top analyst calls
PremiumThe FlyAdobe downgraded, Nio upgraded: Wall Street’s top analyst calls
3M ago
Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study
Premium
The Fly
Immutep says IDMC recommends discontinuation for TACTI-004 Phase III study
3M ago
Immutep downgraded to Neutral from Outperform at Baird
Premium
The Fly
Immutep downgraded to Neutral from Outperform at Baird
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100